What happens when patients stop taking GLP-1 drugs? New study reveals real world insights
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment.
‘Mormon Wives’ star weighs just 99 pounds at 5′ 10″, admits GLP-1 addiction
Layla Taylor reveals her eating disorder struggle on “Mormon Wives.” She weighs just 99 pounds at 5’10” and says she’s unable to stop destructive patterns.
Why Ozempic users are actually spending more on high-end chocolate
A new report from Lindt & Sprüngli suggests households using GLP-1 weight-loss medications are driving stronger growth in premium chocolate sales, even as some research shows overall food spending declines.
GLP-1 Receptor Agonists Linked to Lower Mortality for Patients With Brain Metastases, T2DM
FRIDAY, March 13, 2026 — For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, according to a research…
Wegovy users may have 5 times risk of vision loss than those on Ozempic
Berberine as a natural Ozempic? An analysis of a popular myth
In recent years, berberine has increasingly appeared in the public sphere as a “natural way” to improve metabolism. In social media, it is sometimes compared to incretin drugs and even referred to as “plant-based Ozempic.” Such comparisons suggest a simple mechanism of action and predictable effects.
Persistence With GLP-1 Receptor Agonist Therapy Remains Low Among Those With Overweight, Obesity
THURSDAY, March 12, 2026 — Less than 25 percent of adults with overweight or obesity without diabetes remain on any glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment after 12 months, according to a research letter published online…
Impurity in Some Compounded Tirzepatide ‘Potentially Dangerous,’ Eli Lilly Warns
(MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…
Study Looks at Associations Between Semaglutide and Ischemic Optic Neuropathy
THURSDAY, March 12, 2026 — Formulation- and sex-specific associations are seen for semaglutide use with ischemic optic neuropathy, with increased odds in men and with Wegovy use, according to a study published online March 10 in the British Journal…
Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide
Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.